依據世界衛生組織(WHO)統計，全球約有1 億7 千萬人口感染C 型肝
炎病毒(Hepatitis C Virus, HCV)，台灣亦有92 萬人口為C 型肝炎病患，HCV造成日益嚴重的肝臟疾病。故我們希望合成出具有抗C 型肝炎病毒潛力的化合物，並進一步討論其合成條件與立體結構。我們合成出化合物coumarin carboxylic acids 與benzoimidazol-2-amines 後利用耦合試劑進行醯胺鍵結的合成。使用不同的耦合試劑與活化試劑如：carbodiimide 類型的DCC 與EDCI（WSCI）和Aminium-base reagent 的HBTU 加上活化試劑1-Hydroxybenzotriazole（HOBt）與N-Hydroxysuccinimide（NHS or HOSu）合成所需的醯胺官能基。並藉由核磁共振之氫譜（1H NMR）、質譜儀（FAB Mass）與紅外線光譜（FTIR）判定我們所合成出化合物的結構。並使用核磁共振之氫譜（1H NMR）與分子模擬軟體討論其立體結構而得知化合物的構型。此結果可幫助我們討論結構與活性關係（SAR）時的參考依據。

According to the World Health Organization (WHO) statistics, about 170 million people infected with hepatitis C virus (HCV), and in Taiwan is also a population of 920,000 patients with hepatitis C, HCV causes more serious liver disease. So we hope that synthesis has the potential of anti-hepatitis C compounds, and further more discuss the synthesis conditions and
stereo structure. First, we synthesized coumarin carboxylic acid and benzoimidazol-2-amine
then using coupling reagents for amide bond formation. Using different coupling reagents
and activation reagents, such as carbodiimide type of DCC and EDCI (WSCI) and Aminium-base reagent HBTU with activated reagents, 1-hydroxybenzotriazole (HOBt) and
N-hydroxysuccinimide (NHS or HOSu) to prepare the required amide functional groups.We used nuclear magnetic resonance spectra of hydrogen (1H NMR), mass spectrometry
(FAB Mass) and infrared spectroscopy (FTIR) to confirm our compounds. Then we used 1H NMR and molecular simulation to discuss the stereo structure and conformation. The results
can help us to discuss the structure and activity relationship (SAR).

1. Simmonds, P. Genetic diversity and evolution of hepatitis C virus ? 15 years on. J. Gen. Virol. 2004, 85, 3173–3188.
2. Hoofnagle, J. H. The course and outcome of hepatitis C. Hepatology 2002, 36, S21–S29.
3. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359–362.
4. Simmonds, P.; Bukh, J.; Combet, C.; Deléage, G.; Enomoto, N.; Feinstone, S.; Halfon, P.; Inchauspé, G.; Kuiken, C.; Maertens, G.; Mizokami, M.; Murphy, D. G.; Okamoto, H.; Pawlotsky, J.-M.; Penin, F.; Sablon, E.; Shin-I, T.; Stuyver, L. J.; Thiel, H.-J.; Viazov, S.; Weiner, A. J.; Widell, A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42, 962–973.
5. Wagner, R.; Larson, D. P.; Beno, D. W. A.; Bosse, T. D.; Darbyshire, J. F.; Gao, Y.; Gates, B. D.; He, W.; Henry, R. F.; Hernandez, L. E.; Hutchinson, D. K.; Jiang, W. W.; Kati, W. M.; Klein, L. L.; Koev, G.; Kohlbrenner, W.; Krueger, A. C.; Liu, J.; Liu, Y.; Long, M. A.; Maring, C. J.; Masse, S. V.; Middleton, T.; Montgomery, D. A.; Pratt, J. K.; Stuart, P.; Molla, A.; Kempf, D. J. Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines. J. Med. Chem. 2009, 52, 1659–1669.
6. Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345,
41–52.
7. Pawlotsky J. M.; Gish, R. G. Future therapies for hepatitis C. Antivir. Ther. 2006, 11, 397–488.
8. Alvarez, D.; Dieterich, D. T.; Brau, N.; Moorehead, L.; Ball, L.; Sulkowski, M. S. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J. Viral. Hepatitis. 2006, 13, 683–689.
9. Gish, R. G. Treating HCV with ribavirin analogues and ribavirin-like molecules. J. Antimicrob. Chemother. 2006, 57, 8–13.
10. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure?activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 2006, 49, 4721–4736.
11. Andrzejewska, M.; Mulia, L.; Rivera, C. R.; Tapia, A.; Vilpo, L.; Vilpo, J.; Kazimierczuk, Z. Synthesis, antiprotozoal and anticancer activity of substituted 2-trifluoromethyl- and 2-pentafluoroethylbenzimidazoles. Eur. J. Med. Chem. 2002, 37, 973–978.
12. Gümüş, F; Algül, Ö.; Eren, G.; Eroğlu, H,; Diril, N.; Gür, S.; Özkul, A. Synthesis, cytotoxic activity on MCF-7 cell line and mutagenic activity of platinum(II) complexes with 2-substituted benzimidazole ligands. Eur. J. Med. Chem. 2003, 38, 473–480.
13. Ito, C.; Itoigawa, M.; Mishina, Y.; Filho, V. C.; Enjo, F.; Tokuda, H.; Nishino, H.; Furukawa, H. Chemical constituents of calophyllum brasiliense. 2. structure of three new coumarins and cancer chemopreventive activity of 4-substituted coumarins. J. Nat. Prod. 2003, 66, 368–371.
14. Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.; Mazzorana, M.; Zagotto, G.; Uriarte, E.; Guiotto, A.; Pinna, L. A.; Meggio, F.; Moro, S. Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure?activity relationships. J. Med. Chem. 2008, 51 , 752–759.
15. Robert, S.; Bertolla, C.; Masereel, B.; Dogne, J.-M.; Pochet, L. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J. Med. Chem. 2008, 51, 3077–3080.
16. Kamal, A.; Ramulu, P.; Srinivas, O.; Ramesh, G.; Kumar, P. P. Synthesis of C8-linked pyrrolo[2,1-c][1,4]benzodiazepine?benzimidazole conjugates with remarkable DNA-binding affinity. Bioorg. Med. Chem. Lett. 2004, 14, 4791–4794.
17. Chauhan, P. M. S.; Martins, C. J. A.; Horwell, D. C. Syntheses of novel heterocycles as anticancer agents. Bioorg. Med. Chem. 2005, 13, 3513–3518.
18. Demirayak, S.; Mohsen, U. A.; Karaburun, C. A. Synthesis and anticancer and anti-HIV testing of some pyrazino[1,2-a]benzimidazole derivatives. Eur. J. Med. Chem. 2002, 37, 255–260.
19. Garuti, L.; Roberti, M.; Malagoli, M.; Rossi, T.; Castelli, M. Synthesis and antiproliferative activity of some benzimidazole-4,7-dione derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 2193–2195.
20. Lukevics, E.; Arsenyan, P.; Shestakova, I.; Domracheva, I.; Nesterova, A.; Pudova, O. Synthesis and antitumour activity of trimethylsilylpropyl substituted benzimidazoles. Eur. J. Med. Chem. 2001, 36, 507–515.
21. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C. O.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. H. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 2005, 48, 2972–2984.
22. Reddy, P. N.; Reddy, Y. T.; Rao, M. K.; Rajitha, B. Synthesis and anticancer activity of novel benzimidazole chromenes, thiadiazolylchromenes under microwave irradiation conditions. Heterocycl. Commun. 2003, 9, 647–652
23. Lee, S.; Sivakumar, K.; Shin, W.-S.; Xie, F.; Wang, Q. Synthesis and anti-angiogenesis activity of coumarin derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 4596–4599.
24. Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.; Kukolj, G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis c virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 Cells. J. Med. Chem. 2004, 47, 6884–6892.
25. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; DeRoy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; McKercher, G.; Poupart, M.-A.; Valois, S.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 2004, 14, 967–971.
26. Ishida, T.; Suzuki, T.; Hirashima, S.; Mizutani, K.; Yoshida, A.; Ando, I.; Ikeda, S.; Adachi, T.; Hashimoto, H. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: Identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole. Bioorg. Med. Chem. Lett. 2006, 16, 1859–1863.
27. Hwu, J. R.; Singha, R.; Hong, S. C.; Chang, Y. H.; Das, A. R.; Vliegen, I.; De Clercq, E.; Neyts, J. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral. Res. 2008, 77, 157–162.
28. Neyts, J.; Clercq, E. D.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.; Hong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. Structure?activity relationship of new anti-hepatitis C virus agents: heterobicycle?coumarin conjugates. J. Med. Chem. 2009, 52, 1486–1490.
29. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J. Med. Chem. 2009, 52, 1935–1942.
30. Fisher, M. G.; Gale, P. A.; Light, M. E. A simple benzimidazole-based receptor for barbiturate and urea neutral guests that functions in polar solvent mixtures. New. J. Chem. 2007, 31. 1583–1584
31. Moon, K. S.; Singh, N.; Lee, G. W.; Jang, D. O. Colorimetric anion chemosensor based on 2-aminobenzimidazole: naked-eye detection of biologically important anions. Tetrahedron 2007, 63, 9106–9111.
32. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 2010, 53, 2601–2611.
33. Nakanishi, K.; Solomon, P. H. Infrared Absorption Spectroscopy, 2nd ed.; Holden-Day: Oakland, CA, 1977; p 38.
34. (a) http://accelrys.com/ (b) http://www.molsci.com.tw/index.html